Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| American Oncology Network, Inc.AONC · Entity 88884 | Director | September 20, 2023 | September 20, 2023 |
| Starling Oncology, Inc.TOI · Entity 5327 | Director | March 17, 2023 | March 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
American Oncology Network, Inc.
Report date September 20, 2023 · Filed September 20, 2023
This filing explicitly reported no securities owned.
Starling Oncology, Inc.
Report date March 17, 2023 · Filed March 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 75,427 |
Reported balance
After 2023-03-17 transaction · row 1
1 source rowRow 1 · 2023-03-17 · Grant · Acquired 29,528 · Balance 75,427 F1: Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date. |
| Common stockSEC Table I · non-derivative | IndirectLLC | 4,109,771 |
Reported balance
Holding disclosure · report date 2023-03-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,109,771 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2023 Filed Mar 22, 2023 00:52 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 29,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008831 · wf-form4_167944632508935.xml · nonDerivative · entry 1 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,427 F1 · shares: Represents restricted stock units that vest in full on March 16, 2024, subject to continued service with the Company through such vesting date. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:35 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 22,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001799191-22-000041 · edgardoc.xml · nonDerivative · entry 1 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,899 F1 · price: Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:37 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 7,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007102 · wf-form4_164807861674913.xml · nonDerivative · entry 2 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,191 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:37 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 15,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007102 · wf-form4_164807861674913.xml · nonDerivative · entry 1 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,994 F1 · shares: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. F1 · price: Represents restricted stock units that vest in full on November 12, 2022, subject to continued service with the Company through such vesting date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:55 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 4,109,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-140224 · tm2132979-15_4seq1.xml · nonDerivative · entry 1 SARIN RAVI YANG · CIK 0001555959 · Director OncologyCare Partners, LLC · CIK 0001752450 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,109,771 F1 · acquired: Received in connection with the the business combination between DFP Healthcare Acqusitions Corp. and The Oncology Institute, Inc. (the "Business Combination"). F2 · ownership.nature: Reflects shares owned by OncologyCare Partners, LLC. OncologyCare Holdings, LLC is the manager of OncologyCare Partners, LLC, and, Ravi Sarin serves as the managing member of OncologyCare Holdings, LLC. As a result, Mr. Sarin indirectly has the power to control OncologyCare Partners, LLC, and is deemed to have indirect beneficial ownership of the securities held by OncologyCare Partners, LLC. Read SEC document |
| November 12, 2021 Filed Nov 22, 2021 21:15 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantEarn Out Rights · Derivative | 523,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-142489 · tm2133425-6_4aseq1.xml · derivative · entry 3 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 523,497 Underlying: Common Stock · 523,497 shares Expires not disclosed F4 · derivative.exercise_price: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F1 · price: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement governing the Business Combination. Represents shares acquired in the Business Combination. F3 · price: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F4 · derivative.exercise_date: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F4 · derivative.expiration_date: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F2 · ownership.direct: Reflects securities owned by OncologyCare Partners, LLC. OncologyCare Holdings, LLC is the manager of OncologyCare Partners, LLC, and, Ravi Sarin formerly served as the managing member of OncologyCare Holdings, LLC and continues to have the ability to influence the vote and disposition of the shares in certain circumstances, and thus may be deemed to indirectly beneficially own the shares, which Mr. Ravi disclaims except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2021 Filed Nov 22, 2021 21:15 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantEarn Out Rights · Derivative | 348,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-142489 · tm2133425-6_4aseq1.xml · derivative · entry 2 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 348,998 Underlying: Common Stock · 348,998 shares Expires not disclosed F3 · derivative.exercise_price: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F1 · price: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement governing the Business Combination. Represents shares acquired in the Business Combination. F3 · price: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F3 · derivative.exercise_date: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F3 · derivative.expiration_date: Received as part of the consideration in the Business Combination. Represents the right to receive shares of common stock (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30-day trading period during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control. F2 · ownership.direct: Reflects securities owned by OncologyCare Partners, LLC. OncologyCare Holdings, LLC is the manager of OncologyCare Partners, LLC, and, Ravi Sarin formerly served as the managing member of OncologyCare Holdings, LLC and continues to have the ability to influence the vote and disposition of the shares in certain circumstances, and thus may be deemed to indirectly beneficially own the shares, which Mr. Ravi disclaims except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2021 Filed Nov 22, 2021 21:15 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 4,109,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142489 · tm2133425-6_4aseq1.xml · nonDerivative · entry 1 SARIN RAVI YANG · CIK 0001555959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 4,109,771 F1 · price: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement governing the Business Combination. Represents shares acquired in the Business Combination. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement governing the Business Combination. Represents shares acquired in the Business Combination. F2 · ownership.direct: Reflects securities owned by OncologyCare Partners, LLC. OncologyCare Holdings, LLC is the manager of OncologyCare Partners, LLC, and, Ravi Sarin formerly served as the managing member of OncologyCare Holdings, LLC and continues to have the ability to influence the vote and disposition of the shares in certain circumstances, and thus may be deemed to indirectly beneficially own the shares, which Mr. Ravi disclaims except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.